Bull case
Actuate Therapeutics is favorably positioned because elraglusib has shown meaningful clinical activity across multiple high-need cancers, including 53% clinical responses or disease control in 10 of 19 heavily pretreated Ewing sarcoma and neuroblastoma patients, while higher drug exposure in metastatic pancreatic ductal adenocarcinoma was associated with a stronger survival signal (HR 0.48; p<0.001). The pediatric BEACON2 platform study in June 2026 and the planned oral Phase 1/2 study in 2H26 create two credible catalysts, and the oral formulation’s >95% bioavailability plus modeling for 1–2 tablets daily supports a practical path to better exposure and potentially faster development. Additional upside comes from rare pediatric disease Priority Review Voucher potential worth about $150M to $200M, although management has said the pediatric programs will require more funding.